Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Biotech and pharma: from bad to worse, or better in 2023? Amy Brown and Edwin Elmhirst from Evaluate Vantage, discuss what the coming year is likely to bring.
Evaluate and Treehill Partners discuss the state of play and look for smart ways to get investment and deals moving as we head into 2023.
View the webinar: Don't miss our pharma and biotech outlook to 2028.
Webinar video now available to watch on-demand
2022 got off to an uncertain start for the biopharma industry.
After getting off to a pretty dismal start, what does the rest of the year hold for the biopharma market?